Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BX517
Cat. No.:
0225LY-0736
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BX517 is a powerful and selective pharmaceutical agent used to inhibit PDK1.
Synonym:
PDK1 inhibitor 2; BX 517; 850717-64-5; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; [(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea; (Z)-1-(3-(1-(1h-pyrrol-2-yl)ethylidene)-2-oxoindolin-5-yl)urea; {2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-2,3-dihydro-1H-indol-5-yl}urea
CAS No.:
850717-64-5
Compound CID:
11161844
Formula:
C15H14N4O2
Formula Weight:
282.3
Specification
Targets&IC50:
PDX1: 6 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BX517 can be used in intracellular signaling studies to explore the potent inhibition of PDK1 and its role in oncogenic signaling.
Library Information
Target:
PDK; Akt
Receptor:
Akt2; PDK1
Pathways:
Cytoskeletal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-10
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 177.12 mM
